Jane C Davies Mb, Chb

List of Publications by Year
in descending order

119 papers	9,286 citations	136950 32 h-index	39675 94 g-index
122 all docs	122 docs citations	122 times ranked	6148 citing authors

#	Article	IF	Citations
1	Targeted exhaled breath analysis for detection of Pseudomonas aeruginosa in cystic fibrosis patients. Journal of Cystic Fibrosis, 2022, 21, e28-e34.	0.7	17
2	A Short extension to multiple breath washout provides additional signal of distal airway disease in people with CF: A pilot study. Journal of Cystic Fibrosis, 2022, 21, 146-154.	0.7	0
3	Efficacy and safety of inhaled ENaC inhibitor BI 1265162 in patients with cystic fibrosis: BALANCE-CF 1, a randomised, phase II study. European Respiratory Journal, 2022, 59, 2100746.	6.7	5
4	Impact of cross-sensitivity error correction on representative nitrogen-based multiple breath washout data from clinical trials. Journal of Cystic Fibrosis, 2022, 21, e204-e207.	0.7	17
5	COUNTERPOINT: In the Era of Cystic Fibrosis Transmembrane Regulator Protein Modulator Therapy, Are the Treatment Goals for Adults Now Different From Those for Children With Cystic Fibrosis? No. Chest, 2022, 161, 21-24.	0.8	2
6	Rebuttal From Dr Thursfield etÂal. Chest, 2022, 161, 25.	0.8	0
7	A Phase 3, open-label, 96-week trial to study the safety, tolerability, and efficacy of tezacaftor/ivacaftor in children â‰¥Â6 years of age homozygous for F508del or heterozygous for F508del and a residual function CFTR variant. Journal of Cystic Fibrosis, 2022, 21, 675-683.	0.7	10
8	Curvilinearity provides additional information to lung clearance index only in a minority of children with early cystic fibrosis lung disease. ERJ Open Research, 2022, 8, 00582-2021.	2.6	0
9	An Update on CFTR Modulators as New Therapies for Cystic Fibrosis. Paediatric Drugs, 2022, 24, 321-333.	3.1	18
10	Synergistic Activity of Repurposed Peptide Drug Glatiramer Acetate with Tobramycin against Cystic Fibrosis Pseudomonas aeruginosa. Microbiology Spectrum, 2022, 10, .	3.0	3
11	Updated guidance on the management of children with cystic fibrosis transmembrane conductance regulator-related metabolic syndrome/cystic fibrosis screen positive, inconclusive diagnosis (CRMS/CFSPID). Journal of Cystic Fibrosis, 2021, 20, 810-819.	0.7	62
12	A phase 3, double-blind, parallel-group study to evaluate the efficacy and safety of tezacaftor in combination with ivacaftor in participants 6 through 11 years of age with cystic fibrosis homozygous for F508del or heterozygous for the F508del-CFTR mutation and a residual function mutation. Journal of Cystic Fibrosis, 2021, 20, 68-77.	0.7	37
13	Ivacaftor in Infants Aged 4 to <12 Months with Cystic Fibrosis and a Gating Mutation. Results of a Two-Part Phase 3 Clinical Trial. American Journal of Respiratory and Critical Care Medicine, 2021, 203, 585-593.	5.6	67
14	Pseudomonas aeruginosa in the Cystic Fibrosis Airway: Does It Deserve Its Reputation as a Predatory â€œBullyâ€?. American Journal of Respiratory and Critical Care Medicine, 2021, 203, 1027-1030.	5.6	4
15	Entering the era of highly effective modulator therapies. Pediatric Pulmonology, 2021, 56, S79-S89.	2.0	19
16	Time to get serious about the detection and monitoring of early lung disease in cystic fibrosis. Thorax, 2021, 76, 1255-1265.	5.6	24
17	Optimising equity of access: how should we allocate slots to the most competitive trials in Cystic Fibrosis (CF)?. Journal of Cystic Fibrosis, 2021, 20, 978-985.	0.7	5
18	Transepithelial nasal potential difference in patients with, and at risk of acute respiratory distress syndrome. Thorax, 2021, 76, thoraxjnl-2020-215587.	5.6	1

#	Article	IF	Citations
19	Guiding the rational design of patient-centred drug trials in Cystic Fibrosis: A Delphi study. Journal of Cystic Fibrosis, 2021, 20, 986-993.	0.7	5
20	Cystic fibrosis. Lancet, The, 2021, 397, 2195-2211.	13.7	316
21	A Phase 3 Open-Label Study of Elexacaftor/Tezacaftor/Ivacaftor in Children 6 through 11 Years of Age with Cystic Fibrosis and at Least One F508del Allele. American Journal of Respiratory and Critical Care Medicine, 2021, 203, 1522-1532.	5.6	146
22	Riociguat for the treatment of Phe508del homozygous adults with cystic fibrosis. Journal of Cystic Fibrosis, 2021, 20, 1018-1025.	0.7	5
23	Model Systems to Study the Chronic, Polymicrobial Infections in Cystic Fibrosis: Current Approaches and Exploring Future Directions. MBio, 2021, 12, e0176321.	4.1	26
24	Systematic review of lung clearance index (LCI) in non-cystic fibrosis (CF), non-primary ciliary dyskinesia (PCD) bronchiectasis (Bx). , 2021, , .		0
25	The life rafts sailed; Now let's take stock and set the course ahead (Commentary). Journal of Cystic Fibrosis, 2021, 20, 29-30.	0.7	1
26	Comparison of the airway microbiota in children with chronic suppurative lung disease. BMJ Open Respiratory Research, 2021, 8, e001106.	3.0	3
27	The future of cystic fibrosis care: a global perspective. Lancet Respiratory Medicine,the, 2020, 8, 65-124.	10.7	573
28	Abnormal pro-gly-pro pathway and airway neutrophilia in pediatric cystic fibrosis. Journal of Cystic Fibrosis, 2020, 19, 40-48.	0.7	17
29	Insights into the variability of nasal potential difference, a biomarker of CFTR activity. Journal of Cystic Fibrosis, 2020, 19, 620-626.	0.7	14
30	Selective Sampling of the Lower Airway in Children with Cystic Fibrosis: What Are We Missing?. American Journal of Respiratory and Critical Care Medicine, 2020, 201, 747-748.	5.6	1
31	Integrating the multiple breath washout test into international multicentre trials. Journal of Cystic Fibrosis, 2020, 19, 602-607.	0.7	40
32	Monitoring early stage lung disease in cystic fibrosis. Current Opinion in Pulmonary Medicine, 2020, 26, 671-678.	2.6	16
33	Gene Therapy for Respiratory Diseases: Progress and a Changing Context. Human Gene Therapy, 2020, 31, 911-916.	2.7	5
34	Multiple breath washout in bronchiectasis clinical trials: is it feasible?. ERJ Open Research, 2020, 6, 00363-2019.	2.6	5
35	Inhaled dry powder alginate oligosaccharide in cystic fibrosis: a randomised, double-blind, placebo-controlled, crossover phase 2b study. ERJ Open Research, 2020, 6, 00132-2020.	2.6	17
36	Nitrogen offset in N₂ multiple washout method. ERJ Open Research, 2020, 6, 00043-2020.	2.6	1

#	Article	IF	Citations
37	Horses for courses: Learning from functional tests of pulmonary health?. Pediatric Pulmonology, 2020, 55, 1855-1858.	2.0	4
38	Evaluation of a multiple breath nitrogen washout system in children. Pediatric Pulmonology, 2020, 55, 2108-2114.	2.0	4
39	Cystic fibrosis drug trial design in the era of CFTR modulators associated with substantial clinical benefit: stakeholdersâ€™ consensus view. Journal of Cystic Fibrosis, 2020, 19, 688-695.	0.7	14
40	Building global development strategies for cf therapeutics during a transitional cftr modulator era. Journal of Cystic Fibrosis, 2020, 19, 677-687.	0.7	24
41	â€˜Go for it, dream big, work hard and persistâ€™: A message to the next generation of CF leaders in recognition of International Women's Day 2020. Journal of Cystic Fibrosis, 2020, 19, 184-193.	0.7	3
42	Combination antifungal therapy for Scedosporium species in cystic fibrosis. Pediatric Pulmonology, 2020, 55, 1993-1995.	2.0	8
43	Targeted exhaled breath analysis for detection of Pseudomonas aeruginosa in cystic fibrosis patients. , 2020, , .		0
44	Molecular Therapies for Cystic Fibrosis. , 2019, , 800-811.e3.		2
45	Fair selection of participants in clinical trials: The challenge to push the envelope further. Journal of Cystic Fibrosis, 2019, 18, e48-e50.	0.7	1
46	Training dogs to differentiate Pseudomonas aeruginosa from other cystic fibrosis bacterial pathogens: not to be sniffed at?. European Respiratory Journal, 2019, 54, 1900970.	6.7	8
47	Speeding up access to new drugs for CF: Considerations for clinical trial design and delivery. Journal of Cystic Fibrosis, 2019, 18, 677-684.	0.7	18
48	Theranostics by testing CFTR modulators in patient-derived materials: The current status and a proposal for subjects with rare CFTR mutations. Journal of Cystic Fibrosis, 2019, 18, 685-692.	0.7	30
49	â€œFortunate are those who take the first stepsâ€? The psychosocial impact of novel drug development. Paediatric Respiratory Reviews, 2019, 31, 9-11.	1.8	2
50	Trials and tribulations: The highs and lows of running cystic fibrosis drug studies. Paediatric Respiratory Reviews, 2019, 31, 25-27.	1.8	1
51	Who and why; sharing our experiences of developing a standard operating procedure (SOP) to allocate screening slots for highly competitive cystic fibrosis trials. Journal of Cystic Fibrosis, 2019, 18, e45-e46.	0.7	10
52	An open-label extension study of ivacaftor in children with CF and a CFTR gating mutation initiating treatment at age 2â€“5â€¯years (KLIMB). Journal of Cystic Fibrosis, 2019, 18, 838-843.	0.7	94
53	Chronic infection by controlling inflammation. Nature Microbiology, 2019, 4, 378-379.	13.3	4
54	Children with cystic fibrosis demonstrate no respiratory immunological, infective or physiological, consequences of vitamin D deficiency. Journal of Cystic Fibrosis, 2018, 17, 657-665.	0.7	14

#	Article	IF	Citations
55	Outdoor air pollution and cystic fibrosis. Paediatric Respiratory Reviews, 2018, 28, 80-86.	1.8	20
56	Disease-modifying drug therapy in cystic fibrosis. Paediatric Respiratory Reviews, 2018, 26, 7-9.	1.8	10
57	Recovery of lung function following a pulmonary exacerbation in patients with cystic fibrosis and the G551D-CFTR mutation treated with ivacaftor. Journal of Cystic Fibrosis, 2018, 17, 83-88.	0.7	36
58	Tezacaftor/Ivacaftor in Subjects with Cystic Fibrosis and F508del/F508del-CFTR or F508del/G551D-CFTR. American Journal of Respiratory and Critical Care Medicine, 2018, 197, 214-224.	5.6	152
59	Pooling of bronchoalveolar lavage in children with cystic fibrosis does not adversely affect the microbiological yield or sensitivity in detecting pulmonary inflammation. Journal of Cystic Fibrosis, 2018, 17, 391-399.	0.7	4
60	VX-659â€"Tezacaftorâ€"Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del Alleles. New England Journal of Medicine, 2018, 379, 1599-1611.	27.0	280
61	Predicting the Future of Cystic Fibrosis Lung Disease: Gene Expression Holds Some of the Answers. Annals of the American Thoracic Society, 2018, 15, 556-557.	3.2	1
62	New anti-pseudomonal agents for cystic fibrosis- still needed in the era of small molecule CFTR modulators?. Expert Opinion on Pharmacotherapy, 2018, 19, 1327-1336.	1.8	20
63	Ivacaftor treatment of cystic fibrosis in children aged 12 to <24 months and with a CFTR gating mutation (ARRIVAL): a phase 3 single-arm study. Lancet Respiratory Medicine,the, 2018, 6, 545-553.	10.7	205
64	Home monitoring of respiratory rate from pulse oximetry in children with cystic fibrosis. , 2018, , .		0
65	Preparation for a first-in-man lentivirus trial in patients with cystic fibrosis. Thorax, 2017, 72, 137-147.	5.6	119
66	Efficacy and safety of lumacaftor and ivacaftor in patients aged 6â€"11 years with cystic fibrosis homozygous for F508del-CFTR : a randomised, placebo-controlled phase 3 trial. Lancet Respiratory Medicine,the, 2017, 5, 557-567.	10.7	243
67	Developments in multiple breath washout testing in children with cystic fibrosis. Current Medical Research and Opinion, 2017, 33, 613-620.	1.9	17
68	Where are we with transformational therapies for patients with cystic fibrosis?. Current Opinion in Pharmacology, 2017, 34, 70-75.	3.5	16
69	Clinical trial research in focus: ensuring new cystic fibrosis drugs fulfil their potential. Lancet Respiratory Medicine,the, 2017, 5, 681-683.	10.7	8
70	Tezacaftorâ€"Ivacaftor in Residual-Function Heterozygotes with Cystic Fibrosis. New England Journal of Medicine, 2017, 377, 2024-2035.	27.0	412
71	Clinical Trials of Novel Treatments for Cystic Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2016, 193, 569-571.	5.6	0
72	534. Preparation for a First-in-Man Lentivirus Trial in Cystic Fibrosis Patients. Molecular Therapy, 2016, 24, S214.	8.2	0

#	Article	IF	Citations
73	Current and future treatment options for cystic fibrosis lung disease: latest evidence and clinical implications. Therapeutic Advances in Chronic Disease, 2016, 7, 170-183.	2.5	41
74	Pseudomonas aeruginosainfection in cystic fibrosis: pathophysiological mechanisms and therapeutic approaches. Expert Review of Respiratory Medicine, 2016, 10, 685-697.	2.5	114
75	Cystic fibrosis in 2016: considerable progress, but much more to do. Lancet Respiratory Medicine,the, 2016, 4, 943-945.	10.7	2
76	The effect of CFTR modulation on the disease progression of cystic fibrosis in the era of precision medicine. Journal of Cystic Fibrosis, 2016, 15, e20.	0.7	1
77	Safety, pharmacokinetics, and pharmacodynamics of ivacaftor in patients aged 2â€"5 years with cystic fibrosis and a CFTR gating mutation (KIWI): an open-label, single-arm study. Lancet Respiratory Medicine,the, 2016, 4, 107-115.	10.7	284
78	Antipseudomonal Bacteriophage Reduces Infective Burden and Inflammatory Response in Murine Lung. Antimicrobial Agents and Chemotherapy, 2016, 60, 744-751.	3.2	90
79	Does mass spectrometric breath analysis detectPseudomonas aeruginosain cystic fibrosis?. European Respiratory Journal, 2016, 47, 994-997.	6.7	19
80	A randomised, double-blind, placebo-controlled trial of repeated nebulisation of non-viral cystic fibrosis transmembrane conductance regulator (CFTR) gene therapy in patients with cystic fibrosis. Efficacy and Mechanism Evaluation, 2016, 3, 1-210.	0.7	22
81	Lumacaftorâ€"Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508delCFTR. New England Journal of Medicine, 2015, 373, 220-231.	27.0	1,308
82	Multiple-Breath Washout as a Lung Function Test in Cystic Fibrosis. A Cystic Fibrosis Foundation Workshop Report. Annals of the American Thoracic Society, 2015, 12, 932-939.	3.2	96
83	Multiple breath washouts in children can be shortened without compromising quality. European Respiratory Journal, 2015, 46, 1814-1816.	6.7	12
84	Repeated nebulisation of non-viral CFTR gene therapy in patients with cystic fibrosis: a randomised, double-blind, placebo-controlled, phase 2b trial. Lancet Respiratory Medicine,the, 2015, 3, 684-691.	10.7	344
85	Lung clearance index in cystic fibrosis subjects treated for pulmonary exacerbations. European Respiratory Journal, 2015, 46, 1055-1064.	6.7	61
86	The reproducibility and responsiveness of the lung clearance index in bronchiectasis. European Respiratory Journal, 2015, 46, 1645-1653.	6.7	33
87	Comparison of CF and non CF FRC and LCI values measured with Exhalyzer D and InnocorTMdevices. , 2015, , .		0
88	Cyanide levels found in infected cystic fibrosis sputum inhibit airway ciliary function. European Respiratory Journal, 2014, 44, 1253-1261.	6.7	26
89	Nasal potential difference measurements in diagnosis of cystic fibrosis: An international survey. Journal of Cystic Fibrosis, 2014, 13, 24-28.	0.7	34
90	Long-term safety and efficacy of ivacaftor in patients with cystic fibrosis who have the Gly551Asp-CFTR mutation: a phase 3, open-label extension study (PERSIST). Lancet Respiratory Medicine,the, 2014, 2, 902-910.	10.7	191

#	Article	IF	Citations
91	How to use: bacterial cultures in diagnosing lower respiratory tract infections in cystic fibrosis. Archives of Disease in Childhood: Education and Practice Edition, 2014, 99, 181-187.	0.5	15
92	Efficacy and Safety of Ivacaftor in Patients Aged 6 to 11 Years with Cystic Fibrosis with a G551D Mutation. American Journal of Respiratory and Critical Care Medicine, 2013, 187, 1219-1225.	5.6	449
93	Assessment of clinical response to ivacaftor with lung clearance index in cystic fibrosis patients with a G551D- CFTR mutation and preserved spirometry: a randomised controlled trial. Lancet Respiratory Medicine,the, 2013, 1, 630-638.	10.7	203
94	Cystic fibrosis: bridging the treatment gap in early childhood. Lancet Respiratory Medicine,the, 2013, 1, 433-434.	10.7	3
95	High Rhinovirus Burden in Lower Airways of Children With Cystic Fibrosis. Chest, 2013, 143, 782-790.	0.8	75
96	Current & Emerging Pharmaceutical Treatments for Cystic Fibrosis Lung Disease. , 2013, , .		0
97	Interleukin-17 and Cystic Fibrosis Lung Disease. American Journal of Respiratory and Critical Care Medicine, 2012, 185, 109-110.	5.6	3
98	Modern Molecular Therapies for Respiratory Disease. , 2012, , 309-316.		0
99	A CFTR Potentiator in Patients with Cystic Fibrosis and theG551DMutation. New England Journal of Medicine, 2011, 365, 1663-1672.	27.0	1,920
100	Design of Gene Therapy Trials in CF Patients. Methods in Molecular Biology, 2011, 741, 55-68.	0.9	3
101	Lung Infection in Cystic Fibrosis and Other Chronic Suppurative Lung Diseases. Progress in Respiratory Research, 2010, , 156-172.	0.1	0
102	Gene Therapy for Cystic Fibrosis. Proceedings of the American Thoracic Society, 2010, 7, 408-414.	3.5	33
103	Bugs, Biofilms, and Resistance in Cystic Fibrosis. Respiratory Care, 2009, 54, 628-640.	1.6	106
104	Monitoring Respiratory Disease Severity in Cystic Fibrosis. Respiratory Care, 2009, 54, 606-617.	1.6	47
105	Detection of antibodies to Pseudomonas aeruginosa in serum and oral fluid from patients with cystic fibrosis. Journal of Medical Microbiology, 2007, 56, 670-674.	1.8	18
106	Cystic fibrosis. BMJ: British Medical Journal, 2007, 335, 1255-1259.	2.3	275
107	Response to Mallory: You Are Civilized, but Still Wrong, Dr. Mallory. Pediatric Pulmonology, 2007, 42, 658-658.	2.0	1
108	Gene and cell therapy for cystic fibrosis. Paediatric Respiratory Reviews, 2006, 7, S163-S165.	1.8	13

#	Article	IF	Citations
109	New tests for cystic fibrosis. Paediatric Respiratory Reviews, 2006, 7, S141-S143.	1.8	4
110	Rebuttal: You are wrong, Dr. Malloryâ€‰â€¦. Pediatric Pulmonology, 2006, 41, 1017-1020.	2.0	17
111	Potential Difference Measurements in the Lower Airway of Children with and without Cystic Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2005, 171, 1015-1019.	5.6	34
112	Airway Gene Therapy. Advances in Genetics, 2005, 54, 291-314.	1.8	21
113	Cystic fibrosis modifier genes. Journal of the Royal Society of Medicine, 2005, 98 Suppl 45, 47-54.	2.0	7
114	Research applications of bronchoscopy. Paediatric Respiratory Reviews, 2003, 4, 230-6.	1.8	3
115	Wheezing in infants and pre-school children accounts for a considerable proportion of acute hospital admissions. Paediatric Respiratory Reviews, 2003, 4, 267, 270.	1.8	0
116	Bone marrow stem cells do not repopulate the healthy upper respiratory tract. Pediatric Pulmonology, 2002, 34, 251-256.	2.0	32
117	New therapeutic approaches for cystic fibrosis lung disease. Journal of the Royal Society of Medicine, 2002, 95 Suppl 41, 58-67.	2.0	1
118	Gene therapy for cystic fibrosis. Journal of Gene Medicine, 2001, 3, 409-417.	2.8	58
119	Infection in patients with cystic fibrosis and congenital immune deficiencies. Current Opinion in Infectious Diseases, 1997, 10, 268-274.	3.1	1